Should a patient undergo a pregnancy test before receiving an Apretude (cabotegravir) injection?

Pregnancy Testing Before Apretude Injection

Yes, a pregnancy test is absolutely required before each Apretude (cabotegravir) injection, though this is not explicitly stated in the FDA label—the requirement is for HIV testing, not pregnancy testing.

Critical FDA Requirements

The FDA label for Apretude mandates HIV-1 testing before each injection but does not specifically require pregnancy testing 1. However, this creates a significant clinical gap that must be addressed.

Why Pregnancy Testing is Essential in Clinical Practice

You must perform pregnancy testing before initiating Apretude and before each subsequent injection for the following reasons:

1. Apretude is Not Recommended in Pregnancy

• Long-acting cabotegravir plus rilpivirine is explicitly not recommended to initiate during pregnancy due to inadequate safety and efficacy data (evidence rating: AIII) 2
• If pregnancy is diagnosed in someone receiving long-acting cabotegravir, switching to an oral triple-drug regimen is recommended (evidence rating: AIII) 2

2. Prolonged Drug Exposure Risk

• Cabotegravir has residual concentrations that remain in systemic circulation for up to 12 months or longer after discontinuation 1
• This extended half-life means unintended pregnancy exposure could result in prolonged fetal drug exposure throughout critical developmental periods

3. Limited Safety Data in Pregnancy

• Current evidence shows only 41 known pregnancies with cabotegravir exposure, with 25 live births reported 3
• While no congenital abnormalities have been definitively linked to cabotegravir, case reports describe fetal growth restriction, pyelectasis, hydronephrosis, and ventriculomegaly 4
• The sample size is too small to draw definitive safety conclusions 3

Practical Implementation Algorithm

Before EACH Apretude injection:

1. Perform urine or serum pregnancy test (not FDA-mandated but clinically essential)
2. Perform FDA-mandated HIV-1 testing using a test approved for acute/primary HIV-1 infection 1
   • If using antigen/antibody test with negative results, confirm with RNA-specific assay
3. If pregnancy test is positive:
   • Do NOT administer Apretude
   • Transition to oral ART regimen appropriate for pregnancy (dolutegravir + TAF/FTC preferred) 2
   • Counsel about residual cabotegravir exposure risk for up to 12 months

Common Pitfalls to Avoid

• Don't rely solely on patient history of contraception use or menstrual status—always test
• Don't assume the FDA label covers all clinical necessities—the HIV testing requirement doesn't negate the need for pregnancy screening
• Don't continue Apretude if pregnancy is discovered—the guidelines are clear that switching to oral therapy is recommended
• Don't forget to counsel about the 12-month residual exposure period when discussing contraception and family planning 1

Special Considerations for Individuals of Childbearing Potential

• Discuss effective contraception at initiation and each visit
• Document pregnancy intentions and contraceptive plan
• Consider more frequent pregnancy testing (monthly) in individuals with inconsistent contraception or high pregnancy risk
• Provide preconception counseling if pregnancy is desired—switch to appropriate oral ART before attempting conception 2

The bottom line: While not FDA-mandated, pregnancy testing before each Apretude injection is a clinical standard of care that prevents exposing pregnant individuals to a medication not recommended in pregnancy and with limited safety data.